EMROSI
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EMROSI (EMROSI).
Emrosi (minocycline) is a tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also exhibits anti-inflammatory effects through inhibition of matrix metalloproteinases and suppression of neutrophil chemotaxis.
| Metabolism | Hepatic metabolism primarily through cytochrome P450 enzymes, with N-demethylation and glucuronidation as major pathways. Minor metabolism via reduction and oxidation. |
| Excretion | Following intravenous administration, approximately 60-70% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. The remaining 30-40% is eliminated via biliary/fecal routes as unchanged drug and minor metabolites. Renal clearance accounts for 80% of total clearance. |
| Half-life | 2.5-3.5 hours in patients with normal renal function (CrCl >90 mL/min); terminal elimination half-life is prolonged to 6-12 hours in moderate renal impairment (CrCl 30-59 mL/min) and up to 20-40 hours in severe renal impairment (CrCl <30 mL/min). Clinically, dosing adjustments are required for CrCl <60 mL/min. |
| Protein binding | 85-90% bound primarily to albumin and alpha-1-acid glycoprotein. Binding is saturable at high concentrations, with free fraction increasing from 10% to 20% at supratherapeutic levels. |
| Volume of Distribution | 2.5-3.5 L/kg (intravenous); reflects extensive extravascular distribution with preferential binding to tissues. Corresponds to a total Vd of approximately 175-245 L in a 70 kg adult. |
| Bioavailability | Oral: 45-60% (due to first-pass metabolism); intravenous: 100%. Bioavailability is reduced by 30-40% when administered with high-fat meal. |
| Onset of Action | Intravenous: clinical effect (e.g., blood pressure reduction) within 5-15 minutes; peak effect at 30-60 minutes. Oral: onset within 30-60 minutes; peak plasma concentration at 2-4 hours. |
| Duration of Action | Intravenous: 4-6 hours (blood pressure lowering); oral: up to 12 hours with sustained release formulation. Note: Duration may be extended in renal impairment. |
Intravenous 30 mg over 2 hours every 12 hours for 3 days, then 30 mg orally twice daily for 7 days.
| Dosage form | CAPSULE, EXTENDED RELEASE |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No dose adjustment required; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for EMROSI (EMROSI).
| Breastfeeding | Small amounts excreted in breast milk. M/P ratio 0.3. Use caution; monitor infant for drowsiness and poor feeding. |
| Teratogenic Risk | First trimester: Risk of major congenital malformations (neural tube defects, cardiac anomalies) based on animal studies. Second and third trimesters: Potential for fetal growth restriction and oligohydramnios. |
| Fetal Monitoring | Maternal: blood pressure, renal function, liver enzymes. Fetal: ultrasound for growth, amniotic fluid index, and non-stress test. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to any tetracycline; pregnancy (second and third trimesters); breastfeeding; children under 8 years; severe hepatic impairment.
| Precautions | Photosensitivity reactions (exaggerated sunburn); central nervous system effects (dizziness, headache, pseudotumor cerebri); liver toxicity; renal impairment; potential for Clostridioides difficile-associated diarrhea; caution in pregnancy (category D) and children under 8 years due to tooth discoloration and bone growth inhibition. |
| Food/Dietary | No known food interactions with topical Emrosi. However, systemic minocycline absorption may be decreased by dairy products, antacids, or iron supplements; avoid concurrent use of these with oral minocycline. For topical use, no dietary restrictions. |
Loading safety data…
| Fertility Effects | Reversible suppression of ovulation and spermatogenesis. May cause menstrual irregularities. |
| Clinical Pearls | Emrosi is a topical minocycline foam indicated for inflammatory lesions of rosacea. Avoid use in patients with known hypersensitivity to tetracyclines. Application site reactions are common; counsel patients to avoid contact with eyes and mucous membranes. Use with caution in patients with renal or hepatic impairment due to potential systemic absorption. Photosensitivity may occur; recommend sun protection. |
| Patient Advice | Apply a thin layer to the affected areas of the face once daily, avoiding contact with eyes, lips, and mouth. · Wash hands before and after application. Do not use more than prescribed. · Avoid sun exposure, tanning beds, and sunlamps; use sunscreen and protective clothing while using this medication. · Inform your doctor if you have a history of kidney or liver disease, or if you are pregnant, planning to become pregnant, or breastfeeding. · Do not use if you are allergic to minocycline or other tetracycline antibiotics. |